Document is current
Any future updates will be listed below
-
Authors
Sawada, Haruki https://orcid.org/0000-0002-2458-5918
Kishimoto, Mitsumasa https://orcid.org/0000-0002-4007-1589
Tada, Kurisu https://orcid.org/0000-0002-6450-1993
Deshpande, Gautam A. https://orcid.org/0000-0002-0293-8911
Kobayashi, Daiki https://orcid.org/0000-0002-3641-2088
Okada, Masato https://orcid.org/0000-0002-0357-0127
Benavent, Diego https://orcid.org/0000-0001-9119-5330
Plasencia-Rodriguez, Chamaida https://orcid.org/0000-0003-3503-9047
Navarro-Compán, Victoria https://orcid.org/0000-0002-4527-852X
López-Medina, Clementina https://orcid.org/0000-0002-2309-5837
Molto, Anna https://orcid.org/0000-0003-2246-1986
Dougados, Maxime https://orcid.org/0000-0003-3009-6229
Tamura, Naoto https://orcid.org/0000-0003-1729-2954
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 6 October 2025
First Online: 3 November 2025
Declarations
:
: The study was conducted according to the guidelines for Good Clinical Practice and was approved by the ethical committees of the Juntendo University Hospital (Approval number: 18–211). Written informed consent was obtained from all subjects before enrolment.
: MK received consulting fees and/or honoraria from AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB Pharma. KT has received speaker fees from AbbVie, Amgen, Mitsubishi-Tanabe, Janssen, Eisai, Eli Lilly Japan, Novartis and Kyowa Kirin. MO is a consultant for AbbVie, Eli Lilly, and is on the speaker’s bureau of AbbVie Japan, Eli Lilly and Company, and Ono Pharmaceutical. VN-C: has received research grants/honoraria from AbbVie, Janssen, Lilly, Novartis, Pfizer, and UCB. CL-M received consulting fees and/or honoraria form Lilly, UCB, AbbVie, Janssen and Novartis. NT: has received speaker fees and/or consulting fees from AbbVie, Astellas, Bristol-Myers, Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, Mitsubishi-Tanabe and Novartis. All other authors have declared no conflicts of interest.
